Skip to main content


Table 5 Co-morbid conditions present in QFT negative study subjects

From: Testing for Mycobacterium tuberculosis infection using the QuantiFERON-TB GOLD assay in patients with comorbid conditions in a tertiary care endemic setting

Subjects with Active TB (n = 20)
Co-morbidsFrequency (n, %)TB Ag (IFNγ IU/ml, Median)Mitogen (IFNγ IU/ml, Median)TLC (%)Lymphocytes (%)
None known12 (60)0.025108.118.2
Diabetes3 (15)0.075.798.119.4
Other Endo1 (5)0.038.2713.219
Auto immune diseasea1 (5)0.011.8510.715.9
Malignancy1 (5)0.040.771091
CHD1 (5)0.0110732
Multiple Co-morbidsb1 (5)
Subjects with Non-TB (n = 73) 
(n, %)
(IFNγ IU/ml, Median)
(IFNγ IU/ml, Median)
TLC (%)Lymphocytes
None known24 (33)0.025107.423.6
Chronic Kidney Disease7 (10)
Chronic Lung Disease3 (4)0.047.665.817.9
Diabetes10 (14)07.811111.8
Auto Immune diseasea6 (8)0.01109.417
Malignancy10 (14)0.0656.888.123.5
Epilepsy1 (1)0.03105.838.4
Coronary Heart Disease1 (1)04.2924.412
Multiple co-morbids11 (15)0103621.3
  1. ‘TLC’, Total lymphocyte count; ‘QFT’, Quantiferon TB Gold in tube assay; ‘COPD’, Chronic Obstructive Pulmonary Disorder. Cut-off for QFT positive is ≥0.35 IU/ml. Lymphopenia was determined by lymphocyte counts < 1500 cells/mm3.’a’ autoimmune disease includes Rheumatoid arthritis, Systemic Lupus Erythematosis and mixed connective tissue disorders. ‘b’ patients with multiple diseases including, diabetes, chronic liver disease, chronic kidney disease, endocrine disorders (panhypo-pitutiarism, hypothyroidism, thalassemia and malignancy)